Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mazen Almasry

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
WMJ : Official Publication of the State Medical Society of Wisconsin|January 5, 2024
Uptake Rates of Three COVID-19 Vaccine Doses and Risk Factors for Incomplete Vaccination Among Patients With Inflammatory Bowel Disease Residing in Wisconsin: A Single-Center CohortTrevor L Schell, Miguel A Mailig, Mazen Almasry, et al.
Inflammatory Bowel Diseases|April 9, 2022
Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel DiseaseTrevor L Schell, Keith L Knutson, Sumona Saha, et al.
Clinical and Translational Gastroenterology|May 5, 2025
Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor TherapyFreddy Caldera, Stacey Rolak, Francis A Farraye, et al.
Clinical and Translational Gastroenterology|February 13, 2024
Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor TherapyFreddy Caldera, Stacey Rolak, Francis A Farraye, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
WMJ : Official Publication of the State Medical Society of Wisconsin|January 5, 2024
Uptake Rates of Three COVID-19 Vaccine Doses and Risk Factors for Incomplete Vaccination Among Patients With Inflammatory Bowel Disease Residing in Wisconsin: A Single-Center CohortTrevor L Schell, Miguel A Mailig, Mazen Almasry, et al.
Inflammatory Bowel Diseases|April 9, 2022
Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel DiseaseTrevor L Schell, Keith L Knutson, Sumona Saha, et al.
Clinical and Translational Gastroenterology|May 5, 2025
Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor TherapyFreddy Caldera, Stacey Rolak, Francis A Farraye, et al.
Clinical and Translational Gastroenterology|February 13, 2024
Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor TherapyFreddy Caldera, Stacey Rolak, Francis A Farraye, et al.
Pageof 2